Renaissance Capital logo

Vor Biopharma Priced, Nasdaq: VOR

Preclinical biotech developing cell therapies for hematological diseases.

Industry: Health Care

Latest Trade: $15.56 0.00 (0.0%)

First Day Return: +108.3%

Return from IPO: -13.6%

Industry: Health Care

We are a clinical-stage cell therapy company combining a novel patient engineering approach with targeted therapies to provide a single company solution for patients suffering from hematological malignancies. For many patients, the only way to achieve durable remission or a cure is through hematopoietic stem cell transplant (HSCT). Despite undergoing HSCT, approximately 40% of acute myeloid leukemia (AML) patients relapse and face an extremely poor prognosis, with two-year survival rates of less than 20%. We are developing our lead eHSC product candidate, VOR33, and our companion therapeutic, VCAR33, which together, we believe, have the potential to transform the treatment paradigm for AML and other hematological malignancies. We use genome engineering technology to remove CD33 surface targets from HSCs to create VOR33. Our eHSCs, such as VOR33, are designed to be used with complementary companion therapeutics, such as VCAR33, that would provide tumor-specific killing. VCAR33 is a chimeric antigen receptor (CAR)-T therapy candidate designed to target CD33, a clinically-validated target for AML. A T cell therapy using the same CAR construct as VCAR33 is currently in an investigator-initiated Phase 1/2 trial for the treatment of patients with AML that is sponsored by the National Marrow Donor Program (NMDP), with initial monotherapy proof-of-concept data expected in 2022, depending on the investigator’s timing of data release.
more less
IPO News for Vor Biopharma
more
IPO Data
IPO File Date 01/15/2021
Offer Price $18.00
Price Range $16.00 - $18.00
Offer Shares (mm) 9.8
Deal Size ($mm) $177
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 02/04/2021
Offer Price $18.00
Price Range $16.00 - $18.00
Offer Shares (mm) 9.8
Deal Size ($mm) $177
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Cambridge, MA
Founded 2015
Employees 76
Website www.vorbio.com